vs
ANI PHARMACEUTICALS INC（ANIP）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是ANI PHARMACEUTICALS INC的1.2倍（$297.2M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 4.9%，领先6.2%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -3.2%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $19.7M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 3.0%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
ANIP vs SCVL — 直观对比
营收规模更大
SCVL
是对方的1.2倍
$247.1M
营收增速更快
ANIP
高出32.8%
-3.2%
净利率更高
ANIP
高出6.2%
4.9%
自由现金流更多
ANIP
多$9.4M
$19.7M
两年增速更快
ANIP
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $297.2M |
| 净利润 | $27.5M | $14.6M |
| 毛利率 | — | 37.6% |
| 营业利润率 | 14.1% | 6.3% |
| 净利率 | 11.1% | 4.9% |
| 营收同比 | 29.6% | -3.2% |
| 净利润同比 | 367.5% | -23.9% |
| 每股收益（稀释后） | $1.14 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPSCVL
| Q4 25 | $247.1M | $297.2M | ||
| Q3 25 | $227.8M | $306.4M | ||
| Q2 25 | $211.4M | $277.7M | ||
| Q1 25 | $197.1M | $262.9M | ||
| Q4 24 | $190.6M | $306.9M | ||
| Q3 24 | $148.3M | $332.7M | ||
| Q2 24 | $138.0M | $300.4M | ||
| Q1 24 | $137.4M | $280.2M |
净利润ANIPSCVL
| Q4 25 | $27.5M | $14.6M | ||
| Q3 25 | $26.6M | $19.2M | ||
| Q2 25 | $8.5M | $9.3M | ||
| Q1 25 | $15.7M | $14.7M | ||
| Q4 24 | $-10.3M | $19.2M | ||
| Q3 24 | $-24.2M | $22.6M | ||
| Q2 24 | $-2.3M | $17.3M | ||
| Q1 24 | $18.2M | $15.5M |
毛利率ANIPSCVL
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 34.5% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 36.0% | ||
| Q3 24 | — | 36.1% | ||
| Q2 24 | — | 35.6% | ||
| Q1 24 | — | 35.6% |
营业利润率ANIPSCVL
| Q4 25 | 14.1% | 6.3% | ||
| Q3 25 | 15.9% | 8.2% | ||
| Q2 25 | 6.6% | 4.3% | ||
| Q1 25 | 13.3% | 5.3% | ||
| Q4 24 | -2.3% | 8.0% | ||
| Q3 24 | -13.8% | 9.0% | ||
| Q2 24 | 3.7% | 7.5% | ||
| Q1 24 | 14.8% | 7.1% |
净利率ANIPSCVL
| Q4 25 | 11.1% | 4.9% | ||
| Q3 25 | 11.7% | 6.3% | ||
| Q2 25 | 4.0% | 3.4% | ||
| Q1 25 | 8.0% | 5.6% | ||
| Q4 24 | -5.4% | 6.3% | ||
| Q3 24 | -16.3% | 6.8% | ||
| Q2 24 | -1.7% | 5.8% | ||
| Q1 24 | 13.2% | 5.5% |
每股收益（稀释后）ANIPSCVL
| Q4 25 | $1.14 | $0.53 | ||
| Q3 25 | $1.13 | $0.70 | ||
| Q2 25 | $0.36 | $0.34 | ||
| Q1 25 | $0.69 | $0.53 | ||
| Q4 24 | $-0.45 | $0.70 | ||
| Q3 24 | $-1.27 | $0.82 | ||
| Q2 24 | $-0.14 | $0.63 | ||
| Q1 24 | $0.82 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $107.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $683.2M |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPSCVL
| Q4 25 | $285.6M | $107.7M | ||
| Q3 25 | $262.6M | $91.9M | ||
| Q2 25 | $217.8M | $93.0M | ||
| Q1 25 | $149.8M | $123.1M | ||
| Q4 24 | $144.9M | $91.1M | ||
| Q3 24 | $145.0M | $84.5M | ||
| Q2 24 | $240.1M | $69.5M | ||
| Q1 24 | $228.6M | $111.2M |
股东权益ANIPSCVL
| Q4 25 | $540.7M | $683.2M | ||
| Q3 25 | $505.8M | $670.7M | ||
| Q2 25 | $436.8M | $653.6M | ||
| Q1 25 | $418.6M | $649.0M | ||
| Q4 24 | $403.7M | $635.7M | ||
| Q3 24 | $405.9M | $618.5M | ||
| Q2 24 | $455.8M | $597.8M | ||
| Q1 24 | $452.0M | $583.4M |
总资产ANIPSCVL
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $33.6M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $19.7M |
| 自由现金流率自由现金流/营收 | 11.8% | 6.6% |
| 资本支出强度资本支出/营收 | 0.5% | 4.7% |
| 现金转化率经营现金流/净利润 | 1.10× | 2.30× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $35.1M |
8季度趋势，按日历期对齐
经营现金流ANIPSCVL
| Q4 25 | $30.4M | $33.6M | ||
| Q3 25 | $44.1M | $13.3M | ||
| Q2 25 | $75.8M | $-9.6M | ||
| Q1 25 | $35.0M | $44.5M | ||
| Q4 24 | $15.9M | $17.3M | ||
| Q3 24 | $12.5M | $23.7M | ||
| Q2 24 | $17.4M | $17.1M | ||
| Q1 24 | $18.3M | $53.4M |
自由现金流ANIPSCVL
| Q4 25 | $29.1M | $19.7M | ||
| Q3 25 | $38.0M | $2.2M | ||
| Q2 25 | $71.8M | $-23.0M | ||
| Q1 25 | $32.5M | $36.2M | ||
| Q4 24 | $13.5M | $8.3M | ||
| Q3 24 | $7.7M | $18.2M | ||
| Q2 24 | $13.0M | $6.9M | ||
| Q1 24 | $13.7M | $40.7M |
自由现金流率ANIPSCVL
| Q4 25 | 11.8% | 6.6% | ||
| Q3 25 | 16.7% | 0.7% | ||
| Q2 25 | 34.0% | -8.3% | ||
| Q1 25 | 16.5% | 13.8% | ||
| Q4 24 | 7.1% | 2.7% | ||
| Q3 24 | 5.2% | 5.5% | ||
| Q2 24 | 9.4% | 2.3% | ||
| Q1 24 | 10.0% | 14.5% |
资本支出强度ANIPSCVL
| Q4 25 | 0.5% | 4.7% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 1.9% | 4.8% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 1.3% | 3.0% | ||
| Q3 24 | 3.2% | 1.7% | ||
| Q2 24 | 3.2% | 3.4% | ||
| Q1 24 | 3.3% | 4.5% |
现金转化率ANIPSCVL
| Q4 25 | 1.10× | 2.30× | ||
| Q3 25 | 1.66× | 0.69× | ||
| Q2 25 | 8.87× | -1.03× | ||
| Q1 25 | 2.23× | 3.04× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | 1.00× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SCVL
暂无分部数据
